Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02187783 · ClinicalTrials.gov registry record · Phase 2
LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)
A Phase 2 study of Tumors With CDK4/6 Pathway Activation, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 106
- Enrollment target
- 20
- Study locations
NCT02187783 is a Phase 2 study of Tumors With CDK4/6 Pathway Activation that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 106 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT02187783, a Phase 2 study of Tumors With CDK4/6 Pathway Activation, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 106 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this signal seeking study was to determine whether treatment with LEE011 demonstrates sufficient efficacy in CDK4/6 pathway activated solid tumors and/or hematologic malignancies to warrant further study.
Conditions Studied
Interventions
- DRUG LEE011
Study Locations (20)
Connecticut
- Danbury Hospital - Danbury
- Yale University School of Medicine Smilow Cancer Hospital - New Haven
- Whittingham Cancer Center Norwalk Hospital - Norwalk
- Stamford Hospital Med. Oncology Hematology Res. - Stamford
California
- PCR Oncology - Pismo Beach
- University of California Davis Cancer Center UC Davis Cancer (3) - Sacramento
Georgia
- NorthWest Georgia Oncology Centers NW Georgia Oncology - Marietta
- Harbin Clinic Medical Oncology Clin. Res. - Rome
Indiana
- Indiana University Indiana Univ. - Purdue Univ. - Indianapolis
- Northern Indiana Cancer Research Consortium No. Indiana Cancer Res. - South Bend
Alabama
- University of Alabama at Birmingham - Birmingham
Alaska
- Alaska Clinical Research - Anchorage
Arizona
- Arizona Oncology Associates Dept. Of Onc. - Phoenix
Arkansas
- University of Arkansas/ Arkansas Cancer Research Center UA Medical Sciences - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2014-08-25 |
| Est. Completion | 2018-01-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02187783
The ClinicalTrials.gov registry entry for NCT02187783 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tumors With CDK4/6 Pathway Activation appearing as the primary indexed condition, and to 1 intervention - of which LEE011 is the first listed.
NCT02187783 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Connecticut, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT02187783 about?
NCT02187783 is a clinical study titled "LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)". The purpose of this signal seeking study was to determine whether treatment with LEE011 demonstrates sufficient efficacy in CDK4/6 pathway activated solid tumors and/or hematologic malignancies to warrant further study.
What is the current status of trial NCT02187783?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 106 participants. The study started on 2014-08-25. Estimated completion is 2018-01-17.
What conditions does trial NCT02187783 study?
This clinical trial studies the following conditions: Tumors With CDK4/6 Pathway Activation.
What interventions are being tested in trial NCT02187783?
The interventions under investigation include: LEE011 (DRUG).
Who is sponsoring clinical trial NCT02187783?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02187783 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.